Newsroom

Press Releases

2018201720162015201420132012
20 Jun, 2018
Annual general meeting of the shareholders of the Company, July 26, 2018
13 Jun, 2018
Agreement for the Examination of Cooperation with Wize Pharma; Immaterial Relations with an independent Director
10 May, 2018
Rights Offering Results
7 May, 2018
Rights Exercise Notices by Insiders of BioLight
29 Mar, 2018
Closing of the first stage of the binding agreement of investment in and acquisition in stages of IOPtima
12 Feb, 2018
Update regarding Closing of the first stage of the Binding agreement of investment in and acquisition of IOPtima
22 Nov, 2017
Binding agreement of investment in and acquisition of IOPtima
4 Sep, 2017
DiagnosTear Ltd. - Recruitment of the first participant for clinical trial using the TeaRx ™ technology
29 Aug, 2017
IOPtima - Obtained regulatory approval for the sales and marketing of the IOPtiMate ™ system in Taiwan
25 Jul, 2017
ViSci - Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert
26 Apr, 2017
ViSci - Completion of the Last Patient Treatment in a Phase I/IIa Clinical Trial
20 Apr, 2017
IOPtima - Signing on a Non-Binding Memorandum of Understanding for a Full Purchase
23 Feb, 2017
TeaRx™ Multi-Parameter Diagnostic Assays to be Used in Dry Eye Syndrome Drug Trial
26 Jul, 2016
Successful Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect Non-Invasive Test
19 May, 2016
BioLight Expands Its Product Portfolio With Eye Drops for Dry Eye Syndrome
5 Apr, 2016
BioLight Reports 2015 Financial Results
10 Feb, 2016
BioLight Files Registration Statement for Proposed Initial Public Offering in the United States
7 Jan, 2016
Positive Second Clinical Study Results for its TeaRx™
30 Dec, 2015
BioLight Announces Closing of Joint Investment in IOPtima Subsidiary
21 Dec, 2015
IOPtiMate System Receives Regulatory Approval in Canada
8 Dec, 2015
First IOPtiMate™ System Sale in Portugal
1 Dec, 2015
Third Quarter 2015 Financial Results
30 Nov, 2015
Partnership with Axella Research for CellDetect® Non-Invasive Test for Monitoring Recurrence of Bladder Cancer
25 Nov, 2015
Joint Investment in IOPtima Subsidiary
21 Oct, 2015
Diagnostear - Grant Approval by the Chief Scientist
30 Sep, 2015
IOPtima - Issuance of Israeli Patent
24 Sep, 2015
Eye-D Technology to be Featured at the 5th Annual Partnership Opportunities in Drug Delivery Conference in Boston
2 Sep, 2015
Presentations at Upcoming European Ophthalmology Conferences
31 Aug, 2015
Second Quarter 2015 Financial Results
31 Aug, 2015
Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of Developing BRONJ
13 Aug, 2015
First IOPtiMate™ System Sale in Peru
30 Jun, 2015
EU CE Mark for CellDetect Non-Invasive Test for Detecting Recurrence of Bladder Cancer
15 Jun, 2015
Collaboration with Ora, Inc. for TeaRx™
1 Jun, 2015
First Quarter 2015 Financial Results
1 Jun, 2015
IOPtima - Issuance of Japanese Patent
12 May, 2015
BioLight Has Completed an Upsized Private Placement
21 Apr, 2015
First IOPtiMate™ System Procedures Sale in Romania
13 Apr, 2015
First IOPtiMate™ System Sale in Hungary
5 Apr, 2015
BioLight Increases its Equity Stake in Micromedic
2 Apr, 2015
BioLight Announces Strategic Partnership to Significantly Expand Presence in China
24 Feb, 2015
BioLight Offers to Increase its Equity Stake in Micromedic
11 Feb, 2015
IOPtima - Issuance of Chinese Patent
2 Feb, 2015
CellDetect - Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence
2 Feb, 2015
DiagnosTear - Positive Clinical Study Findings
1 Feb, 2015
IOPtima - Issuance of Israeli Patent
12 Jan, 2015
New Investment in Development of Ophthalmic Drugs
8 Dec, 2014
Distribution Agreement for IOPtiMate™ Systems in Hong Kong and Macao
27 Nov, 2014
First IOPtiMate™ System Sale in Poland
22 Oct, 2014
BioLight to Present at the Canaccord Forum
13 Oct, 2014
IOPtima will Present at the OIS Conference
9 Sep, 2014
First IOPtiMate™ System Sale in Hong Kong
2 Jul, 2014
Issuance of U.S. Patent for the Long-Term Controlled-Release Drug-Delivery Insert Platform
1 Jul, 2014
BioLight Reports Successful Interim Results from Bladder Cancer Clinical Study
30 Jun, 2014
First Patient Enrolled with BioLight’s Controlled-Release Latanoprost Insert
12 Jun, 2014
BioLight Added to the TA-Biomed and the TA-BlueTech Indices on the TASE
29 May, 2014
Distribution Agreement for IOPtiMate™ Systems in China
28 May, 2014
Diagnostear - Grant Approval by the Chief Scientist
27 May, 2014
Micromedic identifies new genetic markers to predict risk of developing BRONJ
14 May, 2014
U.S. Patent Approval for its Formulation of Latanoprost in its Proprietary Controlled Release Insert
31 Mar, 2014
IND Filing to FDA for Phase I/IIa Clinical Trial for its Controlled-Release Latanaprost Insert
23 Mar, 2014
Third Institutional Investor joins BioLight’s Private Placement
19 Mar, 2014
BioLight Announces New Insider
6 Mar, 2014
BioLight Raises NIS 19 Million
2 Mar, 2014
IOPtima Received Regulatory Approval in China
27 Feb, 2014
BioLight to Present at 26th Annual ROTH Conference
27 Feb, 2014
Meeting Summons - March 2014
20 Feb, 2014
BioLight Begins Trading on OTCQX®
10 Feb, 2014
DiagnosTear Starts Clinical Study
3 Feb, 2014
Micromedic Reports Success in Pilot in China
23 Jan, 2014
BioLight ADRs to Begin Trading on the OTC Exchange
12 Jan, 2014
BioLight Files Registration Statement with US SEC
31 Dec, 2013
IOPtima Sigend a Distribution Agreement in Taiwan
10 Oct, 2013
DiagnosTear Ltd. - Grant Approval by the Chief Scientist
22 Sep, 2013
IOPtima Will Commence Selling Its IOPtimate System in Israel
28 Aug, 2013
BioLight Will Work to Register ADR in the US
17 Jul, 2013
Marketing Approval for the IOPtiMate™ in Mexico
20 Jan, 2013
Investment in DES Diagnostics
25 Dec, 2012
Successful Interim Results in a Trial of a Test for Recurrence of Bladder Cancer Cells in Urine Specimens
20 Nov, 2012
Marketing Approval for Zetiq's CellDetect® in China
5 Nov, 2012
BioLight Has Successfully Raised Over $28 Million
30 Oct, 2012
Signing on an Option Agreement with Aerie Pharmaceutical
19 Jun, 2012
BioLight Signed a Non-Binding MOU for a License Option in the Glaucoma Field